SARS ‐ CoV ‐2 convalescent plasma for the controlled clinical trial “ COVIC ‐19”: Experience from collection of very high‐titer plasma from superimmunized individuals
Transfusion · 2025
DOI: 10.1111/trf.18394 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Transfusion, 2025. Verfasst von Simone Hoffmann und 17 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University…. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Antibodies, Viral. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union, Bundesministerium für Bildung und Forschung, European Commission.
Abstract (Originalsprache)
Background
COVID‐19 convalescent plasma (CCP) is a treatment option for COVID‐19. Understanding of donor and product characteristics is important for optimization of CCP therapy. We report the experience of collection of very high‐titer CCP for the trial “A randomized open‐label trial of early, very high‐titer convalescent plasma therapy in clinically vulnerable individuals with mild COVID‐19” (COVIC‐19) (NCT05271929). Study Design and Methods Individuals who had recovered from COVID‐19 and had ≥1 dose of a SARS‐CoV‐2 vaccine were recruited as donors for CCP. Anti‐SARS‐CoV‐2 antibodies were measured by ELISA, and neutralization capacity against SARS‐CoV‐2 variants was assessed in surrogate and pseudovirus‐neutralization assays. Correlation of antibody titers with donor characteristics and antibody kinetics was analyzed.
Results
We recruited 688 potential donors. 41.4% of individuals had antibody concentrations of ≥4000 BAU/ml (anti‐SARS‐CoV‐2 IgG ELISA [QuantiVac]). Concentrations did not significantly differ by sex or ABO type, but were higher among those who had received at least three vaccinations. Highest titers were observed in those with a breakthrough infection after two vaccinations, followed by a booster (median 5374 BAU/mL) or breakthrough infection after the 3rd or 4th vaccination (median 3846 BAU/mL). Ultimately, 172 eligible individuals donated CCP with a median concentration of 6858 BAU/mL (range 4015–22,923 BAU/mL).
Discussion
We demonstrate the feasibility of the collection of very high‐titer CCP products under a harmonized protocol for a randomized clinical trial, but it requires substantial donor selection, appropriate antibody assays, rapid succession of screening, and apheresis to take advantage of the short period of very high antibody concentrations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm; and Institute of Transfusion Medicine, University Ulm,…
- Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
- Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Transfusion Service Baden-Württemberg - Hessen, Mannheim, Germany.
- Institute of Transfusion Medicine and Immunohematology, German Red Cross Blood Transfusion Service Baden-Württemberg - Hessen, Frankfurt, Germany.
- Institute of Transfusion Medicine Dresden, German Red Cross Blood Transfusion Service Nord-Ost gGmbH, Dresden, Germany.
- Institute of Transfusion Medicine Plauen, German Red Cross Blood Transfusion Service Nord-Ost gGmbH, Plauen, Germany.
ORCID-Profile: Simone Hoffmann, Michael Schmidt, Sixten Körper
Förderung
- European Union
- Bundesministerium für Bildung und Forschung
- European Commission
Zitieren
APA
Hoffmann, S., Seidel, A., Ludwig, C., Vieweg, C., Müller, R., Hofmann, H., Jahrsdörfer, B., Wuchter, P., Klüter, H., Schmidt, M., Johnsen, M., Burkhardt, T., Appl, T., Schrezenmeier, E., Münch, J., Tiberghien, P., Schrezenmeier, H., & Körper, S. (2025). SARS ‐ CoV ‐2 convalescent plasma for the controlled clinical trial “ COVIC ‐19”: Experience from collection of very high‐titer plasma from superimmunized individuals. Transfusion. https://doi.org/10.1111/trf.18394
Vancouver
Hoffmann S, Seidel A, Ludwig C, Vieweg C, Müller R, Hofmann H, et al. SARS ‐ CoV ‐2 convalescent plasma for the controlled clinical trial “ COVIC ‐19”: Experience from collection of very high‐titer plasma from superimmunized individuals. Transfusion. 2025. doi:10.1111/trf.18394
BibTeX
@article{Hoffmann2025,
author = {Hoffmann, Simone and Seidel, Alina and Ludwig, Carolin and Vieweg, Christiane and Müller, Rebecca and Hofmann, Henrike and Jahrsdörfer, Bernd and Wuchter, Patrick and Klüter, Harald and Schmidt, Michael and Johnsen, Matthias and Burkhardt, Thomas and Appl, Thomas and Schrezenmeier, Eva and Münch, Jan and Tiberghien, Pierre and Schrezenmeier, Hubert and Körper, Sixten},
title = {SARS ‐ CoV ‐2 convalescent plasma for the controlled clinical trial “ COVIC ‐19”: Experience from collection of very high‐titer plasma from superimmunized individuals},
journal = {Transfusion},
year = {2025},
doi = {10.1111/trf.18394}
}
EUVIMED